Dose escalation with proton-beam boost for low-risk prostate cancer

被引：2
|
作者：
Trabulsi, E. J.
Valicenti, R. K. [1 ]
机构：
[1] Thomas Jefferson Univ, Dept Radiat Oncol, Clin Div, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA
来源：
NATURE CLINICAL PRACTICE UROLOGY | 2006年 / 3卷 / 05期
关键词：
biochemical failure; conformal radiotherapy; dose; morbidity; prostate cancer;
D O I：
10.1038/ncpuro0477
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：256 / 257
页数：2
相关论文
共 50 条
  • [21] BIOLOGICALLY EFFECTIVE DOSE (BED) CORRELATION WITH BIOCHEMICAL CONTROL AFTER LOW-DOSE RATE PROSTATE BRACHYTHERAPY FOR CLINICALLY LOW-RISK PROSTATE CANCER
    Miles, Edward F.
    Nelson, John W.
    Alkaissi, Ali K.
    Das, Shiva
    Clough, Robert W.
    Broadwater, Gloria
    Anscher, Mitchell S.
    Chino, Junzo P.
    Oleson, James R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (01): : 139 - 146
  • [22] Is There a Role for Active Surveillance in Low-Risk Prostate Cancer?
    Augustin, Herbert
    Mayerhofer, Katrin
    Seles, Maximilian
    Pummer, Karl
    UROLOGIA INTERNATIONALIS, 2015, 95 (02) : 125 - 131
  • [23] External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer
    Strom, Tobin J.
    Hutchinson, Sean Z.
    Shrinath, Kushagra
    Cruz, Alex A.
    Figura, Nicholas B.
    Nethers, Kevin
    Biagioli, Matthew C.
    Fernandez, Daniel C.
    Heysek, Randy V.
    Wilder, Richard B.
    INTERNATIONAL BRAZ J UROL, 2014, 40 (04): : 474 - 483
  • [24] Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer
    D'Ambrosio, David J.
    Pollack, Alan
    Harris, Eleanor E. R.
    Price, Robert A.
    Verhey, Lynn J.
    Roach, Mack, III
    Demanes, D. Jeffrey
    Steinberg, Michael L.
    Potters, Louis
    Wallner, Paul E.
    Konski, Andre
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (03): : 671 - 677
  • [25] Low-risk prostate cancer and low testosterone: What are the acceptable alternatives?
    Soloway M.
    Current Urology Reports, 2009, 10 (6) : 413 - 417
  • [26] Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?
    Shakespeare, Thomas P.
    Wilcox, Shea W.
    Aherne, Noel J.
    ONCOTARGETS AND THERAPY, 2016, 9 : 2819 - 2824
  • [27] Potential interest of developing an integrated boost dose escalation for stereotactic irradiation of primary prostate cancer
    Udrescu, C.
    Rouviere, O.
    Enachescu, C.
    Sotton, M. -P.
    Bouffard-Vercelli, J.
    Jalade, P.
    Chapet, O.
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2014, 30 (03): : 320 - 325
  • [28] Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: Potential for dose escalation
    Hsu, ICJ
    Pickett, B
    Shinohara, K
    Krieg, R
    Roach, M
    Phillips, T
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (04): : 851 - 858
  • [29] Is Low-risk Prostate Cancer Really Low-risk? Consider Factors Affecting Biochemical Recurrence and Tumour Upgrade
    Sogutdelen, Emrullah
    Citamak, Burak
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2023, 33 (02): : 193 - 198
  • [30] High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer
    Cendales, Ricardo
    Alwers, Elizabeth
    Cifuentes, Javier
    Bobadilla, Ivan
    Torres, Felipe
    Arbelaez, Juan
    Goiton, Armando
    Cortes, Helber
    Acevedo, Yenny
    Quintero, Paulo
    Vasquez, Jaider
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2015, 7 (01) : 10 - 16
12345